Loading...
XNAS
ALT
Market cap277mUSD
Jul 09, Last price  
3.12USD
1D
0.32%
1Q
-3.70%
Jan 2017
-99.68%
IPO
-99.85%
Name

Altimmune Inc

Chart & Performance

D1W1MN
XNAS:ALT chart
P/E
—
P/S
6,716.17
EPS
—
Div Yield, %
—
Shrs. gr., 5y
28.00%
Rev. gr., 5y
-65.33%
Revenues
41k
+105.00%
1,847,71214,643,61532,911,32827,549,97820,993,60524,266,27425,175,88717,912,60710,190,20510,640,6605,230,19641,50310,331,1685,801,4018,185,0274,410,000-68,000426,00020,00041,000
Net income
-88m
L-7.33%
1,016,334-13,587,303-36,415,113-32,279,760-34,849,277-3,797,573-4,920,115-11,718,353-9,955,395-3,440,705193,854,173-46,425,390-39,171,152-20,520,131-49,044,477-97,090,000-84,713,000-88,447,000-95,059,000-88,093,000
CFO
-68m
L-15.42%
1,528,426-13,636,712-13,198,574-28,145,650-14,864,577-7,808,553-2,322,906-7,168,204-8,474,042-3,215,981201,508,238-20,214,079-9,388,908-9,601,997-34,305,815-78,238,000-62,586,000-75,810,000-79,848,000-67,535,000
Dividend
Jan 20, 2017291.0033 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
URL
https://altimmune.com/
IPO date
Oct 06, 2005
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT